Natural killer cell activity and progression-free survival in ovarian cancer
other
OA: closed
public-domain-us
AI-generated summary
Lower natural killer cell activity at primary treatment correlated with disease progression in advanced ovarian cancer patients, and activity significantly reduced upon clinical progression.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
A longitudinal evaluation of the natural killer (NK) cell activity of peripheral blood lymphocytes was performed in 17 patients with advanced ovarian cancer (treated surgically and with subsequent multiagent chemotherapy) for a median follow-up period of 32 months. At the time of primary treatment, the mean value of NK cell activity was significantly lower in patients who then had disease progression (p < 0.05) than in patients with progression-free survival. During the follow-up period, no significant modifications of the NK cell activity were observed; only at the time of clinical disease progression did the NK cell activity show a significant reduction. We conclude that the NK cell activity is a potentially important prognostic factor.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-09-20T09:27:46.357103+00:00
- pubmed
- last seen: 2026-05-13T22:11:44.647872+00:00
- unpaywall
- last seen: 2026-09-25T06:33:09.130943+00:00
License: public-domain-us
· commercial use OK
· attribution required
Courtesy of the U.S. National Library of Medicine
Courtesy of the U.S. National Library of Medicine